Nifluril Adultes (Morniflumate)

Morniflumate, the active ingredient in Nifluril Adultes, is a non‑steroidal anti‑inflammatory drug (fenamate) presented as a rectal formulation for local anti‑inflammatory and analgesic use. It is employed to relieve pain and inflammation in musculoskeletal conditions.

GNH USA supplies Nifluril Adultes as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple jurisdictions. Clients benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical support throughout the procurement process.

Morniflumate is indicated for inflammatory and painful conditions of the musculoskeletal system, acting primarily on joint and soft‑tissue inflammation. - Rheumatoid arthritis: reduces joint swelling, pain and stiffness, improving functional ability. - Osteoarthritis: alleviates chronic joint pain and inflammation, supporting mobility. - Acute musculoskeletal pain: provides rapid analgesic and anti‑inflammatory relief after injury or surgery.

Morniflumate, like other NSAIDs, may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Abdominal discomfort or dyspepsia - Nausea or vomiting - Diarrhoea - Headache - Local rectal irritation - Dizziness

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding - Hepatic dysfunction or jaundice - Renal impairment or acute kidney injury - Severe skin reactions such as Stevens‑Johnson syndrome - Anaphylactic or anaphylactoid reactions - Cardiovascular events including hypertension or thrombotic episodes

When prescribing or dispensing Morniflumate, clinicians should observe several safety precautions to minimise risk. - Assess gastrointestinal risk: evaluate history of ulcers, bleeding or concurrent NSAID use. - Monitor liver function: perform baseline and periodic hepatic enzyme tests. - Evaluate renal function: check serum creatinine and adjust use in renal impairment. - Use the lowest effective dose: limit duration to the shortest period necessary for symptom control. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Morniflumate can interact with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Corticosteroids: heightened ulceration risk. - Lithium: elevated lithium serum levels. - Methotrexate: reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: risk of renal impairment and electrolyte imbalance. - Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding tendency. - Antihypertensive agents: potential attenuation of blood pressure control. - Cyclosporine: enhanced nephrotoxicity.